Full Name
Varia Kirchner
Job Title
Associate Professor of Surgery
Company/Institution/ Organization
Stanford
Speaker Bio
Dr. Kirchner is an Associate Professor of Surgery in the Division of Abdominal Transplantation at Stanford University. Her clinical practice encompasses adult and pediatric liver and kidney transplantation from living and deceased donors, as well as hepato-pancreato-biliary surgery, with a particular focus on total pancreatectomy with islet auto-transplantation (TPIAT) for chronic pancreatitis.
She serves as Associate Vice Chair for Community Engagement in Stanford’s Department of Surgery, where she leads Surgical Innovation Day and directs career development program for fellows and chief residents.
Dr. Kirchner is an active member of the International Liver Transplantation Society (ILTS), the American Society of Transplant Surgeons (ASTS), and the Americas Hepato-Pancreato-Biliary Association (AHPBA). She has held leadership roles including Chair of the ILTS Vanguard Committee and Chair of the ASTS Vanguard Committee, and currently serves as Vice Chair of the AHPBA Research Committee.
Her research focuses on ex vivo organ regeneration, leveraging adult and induced pluripotent stem cells, and on understanding and reversing mechanisms of aging, aimed at optimizing existing therapies and developing new minimally invasive approaches for end-stage organ disease.
She serves as Associate Vice Chair for Community Engagement in Stanford’s Department of Surgery, where she leads Surgical Innovation Day and directs career development program for fellows and chief residents.
Dr. Kirchner is an active member of the International Liver Transplantation Society (ILTS), the American Society of Transplant Surgeons (ASTS), and the Americas Hepato-Pancreato-Biliary Association (AHPBA). She has held leadership roles including Chair of the ILTS Vanguard Committee and Chair of the ASTS Vanguard Committee, and currently serves as Vice Chair of the AHPBA Research Committee.
Her research focuses on ex vivo organ regeneration, leveraging adult and induced pluripotent stem cells, and on understanding and reversing mechanisms of aging, aimed at optimizing existing therapies and developing new minimally invasive approaches for end-stage organ disease.
Speaking At
